Outdoor lifestyle and equipment company Clarus (NASDAQ:CLAR) will be announcing earnings results this Thursday afternoon. Here’s what to expect. Clarus beat analysts’ revenue expectations by 7.5% last ...

As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So take a moment to sympathize with the long term shareholders of Clarus ...

Some two years after braving the pandemic to launch its oral testosterone replacement tablet Jatenzo, Clarus Therapeutics is in dire straits. The company hopes layoffs and R&D culls can help right the ...

Clarus (NASDAQ:CLAR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ...

Northbrook-based pharmaceutical company Clarus Therapeutics Holdings filed for Chapter 11 bankruptcy protection and is seeking court authorization to sell off its only product, testosterone deficiency ...

Clarus Corporation promotes Tripp Wyckoff as Managing Director of Adventure and announces €7.8 million divestiture of PIEPS brand. Clarus Corporation has announced its financial results for the first ...